Mycobacterium tuberculosis septic shock

Chest

Volumn 144, Issue 2, 2013, Pages 474-482

  Kethireddy, Shravan ^a   Light, R Bruce ^a   Mirzanejad, Yazdan ^b   Maki, Dennis ^e   Arabi, Yaseen ^h   Lapinsky, Stephen ^c   Simon, David ^f   Kumar, Aseem ^d   Parrillo, Joseph E ^g   Kumar, Anand ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b SURREY MEMORIAL HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d LAURENTIAN UNIVERSITY   (Canada)

^e University of Wisconsin Health   (United States)

^f RUSH UNIVERSITY   (United States)

^g HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^h KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULOSTATIC AGENT;

ADULT; ANTIMICROBIAL THERAPY; APACHE; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; EXTRAPULMONARY TUBERCULOSIS; FEMALE; FLUID RESUSCITATION; GRAM STAINING; HUMAN; HYPOTENSION; LABORATORY TEST; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; PRESCRIPTION; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; RISK FACTOR; SEPTIC SHOCK; SURVIVAL RATE;

EID: 84881493873     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-1286     Document Type: Article

References (22)

1. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA. 1999; 282 (7): 677-686.
2. World Health Organization. Global Tuberculosis Control. Geneva, Switzerland: World Health Organization; 2010:1-205.
3. Ellis E, Gallant V, Scholten D, Dawson K, Phypers M. Tuberculosis in Canada 2009 Pre-release. Ottawa, ON, Canada: Public Health Agency of Canada; 2010: 1-7.
4. Centers for Disease Control and Prevention (CDC). Trends in tuberculosis-United States, 2010. MMWR Morb Mortal Wkly Rep. 2011; 60 (11): 333-337.
5. Kumar A, Zarychanski R, Light B, et al; Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med. 2010; 38 (9): 1773-1785.
6. Bone RC, Balk RA, Cerra FB, et al; The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Defi nitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 1992; 101 (6): 1644-1655.
7. Kumar A, Ellis P, Arabi Y, et al; Cooperative Antimicrobial Therapy of Septic Shock Database Research Group. Initiation of inappropriate antimicrobial therapy results in a fi vefold reduction of survival in human septic shock. Chest. 2009; 136 (5): 1237-1248.
8. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006; 34 (6): 1589-1596.
9. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classifi cation system. Crit Care Med. 1985; 13 (10): 818-829.
10. Shalhoub RJ, Antoniou LD. The mechanism of hyponatremia in pulmonary tuberculosis. Ann Intern Med. 1969; 70 (5): 943-962.
11. Lynen L, Phan S, Prem Prey S, et al. Does hyponatremia have a value in the diagnosis of extrapulmonary tuberculosis in HIV-1 infected patients in Cambodia? The Open Infectious Diseases Journal. 2007; 1: 1-3.
12. United Nations. Tuberculosis death rate per year per 100,000 population (mid-point). In: Millennium Development Goals Report 2011. New York, NY: Department of Public Information, United Nations; 2011.
13. Penner C, Roberts D, Kunimoto D, Manfreda J, Long R. Tuberculosis as a primary cause of respiratory failure requiring mechanical ventilation. Am J Respir Crit Care Med. 1995; 151 (3 pt 1): 867-872.
14. Zahar JR, Azoulay E, Klement E, et al. Delayed treatment contributes to mortality in ICU patients with severe active pulmonary tuberculosis and acute respiratory failure. Intensive Care Med. 2001; 27 (3): 513-520.
15. CDC. Mortality among patients with tuberculosis and associations with HIV status-United States, 1993-2008. MMWR Morb MortalWkly Rep. 2010; 59 (46): 1509-1513.
16. Friedman LN, Williams MT, Singh TP, Frieden TR. Tuberculosis, AIDS, and death among substance abusers on welfare in New York City. N Engl J Med. 1996; 334 (13): 828-833.
17. Hanrahan CF, Golub JE, Mohapi L, et al. Body mass index and risk of tuberculosis and death. AIDS. 2010; 24(10): 1501-1508.
18. Zheng W, McLerran DF, Rolland B, et al. Association between body-mass index and risk of death in more than 1 million Asians. N Engl J Med. 2011; 364 (8): 719-729.
19. Chiu YS, Wang JT, Chang SC, et al. Mycobacterium tuberculosis bacteremia in HIV-negative patients. J Formos Med Assoc. 2007; 106 (5): 355-364.
20. American Thoracic Society, CDC, Infectious Diseases Society of America. Treatment of tuberculosis. Morbidity and Mortality Weekly Report. 2003; 52 (RR-11): 1-74.
21. Abu-Amero KK. Status of antituberculosis drug resistance in Saudi Arabia 1979-98. East Mediterr Health J. 2002; 8 (4-5): 664-670.
22. Al-Tawfi q JA, Al-Muraikhy AA, Abed MS. Susceptibility pattern and epidemiology of Mycobacterium tuberculosis in a Saudi Arabian hospital: a 15-year study from 1989 to 2003. Chest. 2005; 128 (5): 3229-3232.